We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A pair of reports issued by the federal government indicate the increased use of generic drugs will provide more significant cost savings to consumers than practices such as drug importation and price controls.
President Bush nominated Environmental Protection Agency (EPA) Administrator Michael Leavitt Dec. 13 to become the next secretary of HHS — a decision that surprised Washington observers who had expected former FDA Commissioner Mark McClellan to get the nod.
The HHS did not work with industry to produce the vaccines and drugs necessary to respond to a biological or chemical terrorist attack, said the former head of the HHS office that oversees biodefense efforts.
Recent accomplishments by the HHS’ Office of Inspector General (OIG) include securing a $430 million settlement from Pfizer’s Warner-Lambert unit to resolve allegations that the firm caused the submission of false and/or fraudulent claims to Medicaid through off-label marketing of the epilepsy drug Neurontin (gabapentin).
President Bush has tapped Environmental Protection Agency (EPA) Administrator Michael Leavitt to become the next secretary of HHS — a decision that surprised Washington observers who had expected the job to go to former FDA Commissioner Mark McClellan.
The former head of the HHS office that oversees biodefense efforts has criticized the department for not working with industry to produce the vaccines and drugs necessary to respond to a biological or chemical terrorist attack and called for the creation of a new federal office to coordinate U.S. biodefense activities.
NIH has initiated human trials of a preventive vaccine against the respiratory disease SARS, demonstrating a model for research that could greatly speed vaccine development, the agency said.
Michael Leavitt, administrator of the Environmental Protection Agency (EPA), has been nominated to become the next secretary of HHS — a decision that surprised Washington observers who had expected the job to go to former FDA Commissioner Mark McClellan.
President Bush nominated Environmental Protection Agency (EPA) Administrator Michael Leavitt yesterday to become the next secretary of HHS — a decision that surprised Washington observers who had expected former FDA Commissioner Mark McClellan to get the nod.
The HHS' Office of Inspector General (OIG) has highlighted recent accomplishments, including securing a $430 million settlement from Pfizer's Warner-Lambert unit to resolve allegations that it caused the submission of false and/or fraudulent claims to Medicaid through off-label marketing of the epilepsy drug Neurontin (gabapentin).